Financial Analysis: Charlie’s (OTCMKTS:CHUC) versus Mind Medicine (MindMed) (NASDAQ:MNMD)

Charlie’s (OTCMKTS:CHUCGet Rating) and Mind Medicine (MindMed) (NASDAQ:MNMDGet Rating) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Insider and Institutional Ownership

10.8% of Mind Medicine (MindMed) shares are owned by institutional investors. 50.5% of Charlie’s shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Charlie’s and Mind Medicine (MindMed), as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Charlie’s 0 0 0 0 N/A
Mind Medicine (MindMed) 0 0 2 0 3.00

Mind Medicine (MindMed) has a consensus price target of 8.00, suggesting a potential upside of 900.00%. Given Mind Medicine (MindMed)’s higher probable upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than Charlie’s.


This table compares Charlie’s and Mind Medicine (MindMed)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Charlie’s 22.37% -93.54% 60.00%
Mind Medicine (MindMed) N/A -55.27% -51.10%

Earnings & Valuation

This table compares Charlie’s and Mind Medicine (MindMed)’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Charlie’s $21.50 million 1.01 $4.81 million N/A N/A
Mind Medicine (MindMed) N/A N/A -$93.04 million -0.23 -3.48

Charlie’s has higher revenue and earnings than Mind Medicine (MindMed).


Charlie’s beats Mind Medicine (MindMed) on 5 of the 9 factors compared between the two stocks.

About Charlie’s (Get Rating)

Charlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes e-cigarette liquids and vaping systems in the United States and internationally. The company also offers energy drink under the Bazi brand name. It sells its products through distributors, specialty retailers, and third-party online resellers to approximately 80 countries, primarily, including the United Kingdom, Italy, Spain, Belgium, Australia, Sweden, and Canada. The company was formerly known as True Drinks Holdings, Inc. and changed its name to Charlie's Holdings, Inc. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.

About Mind Medicine (MindMed) (Get Rating)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Receive News & Ratings for Charlie's Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charlie's and related companies with's FREE daily email newsletter.